Touch

Touchlight is a UK-based biotechnology company and CDMO that has pioneered a revolutionary enzymatic DNA production platform. Its proprietary "doggybone DNA" (dbDNA) technology provides a synthetic, cell-free alternative to traditional bacterial fermentation, enabling the rapid and scalable manufacture of high-purity DNA. This platform is being deployed across a wide range of genetic medicines, including mRNA vaccines, viral vectors, and gene therapies, through both internal development and high-profile partnerships with companies like GSK and Pfizer. The company's technology addresses critical bottlenecks in the supply chain for advanced therapies by offering significantly faster turnaround times and improved safety profiles.